Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 6:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 711 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atopic Clear all
Active, not recruiting Phase 2 Interventional

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

NCT05769777
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
22
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Bryant, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 27, 2026, 6:21 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis

NCT03747575
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
MSTT1041A, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Colorado Springs, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 27, 2026, 6:21 AM EDT
Terminated No phase listed Observational

Evaluation and Long-Term Follow-Up of Patients With Allergic and Inflammatory Disorders

NCT00557895
View directory record Official record
Conditions
Allergy, Asthma, Allergic Rhinitis, Mastocytosis, Atopic Dermatitis, Food Allergy
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 80 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 27, 2026, 6:21 AM EDT
Terminated Phase 4 Interventional Results available

A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD

NCT03539601
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole ointment, 2%, Hydrocortisone butyrate cream, 0.1%, Pimecrolimus cream, 1%, Crisaborole Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
10
States / cities
Bryant, Arkansas • Encinitas, California • Orange Park, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 27, 2026, 6:21 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis

NCT04021862
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Bermekimab Monoclonal Antibody, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
17
States / cities
Huntington Beach, California • Coral Gables, Florida • Doral, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 27, 2026, 6:21 AM EDT
Completed Phase 3 Interventional Results available

Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

NCT04804605
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
1,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
76
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bryant, Arkansas + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 27, 2026, 6:21 AM EDT
Terminated No phase listed Observational

A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis

NCT00475605
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
LEO Pharma
Industry
Eligibility
Up to 16 Years
Enrollment
8,071 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
198
States / cities
Alabaster, Alabama • Anniston, Alabama • Birmingham, Alabama + 155 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 27, 2026, 6:21 AM EDT
Completed Phase 1 Interventional

Effect of Different Skin Creams on TEWL

NCT03663673
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
EpiCeram, Aveeno Daily Moisturising Sheer Hydration Lotion®
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Day to 40 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 27, 2026, 6:21 AM EDT
Completed Phase 2 Interventional Results available

Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC)

NCT00914186
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
TS022, Vehicle
Drug
Lead sponsor
Taisho Pharmaceutical R&D Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
La Jolla, California • San Diego, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2011 · Synced Oct 27, 2026, 6:21 AM EDT
Terminated Phase 4 Interventional Results available

Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis

NCT05200403
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole 2%, Vehicle treatment, Accelerometry device for children, Accelerometry device for adult caregivers
Drug · Device
Lead sponsor
Boston University
Other
Eligibility
3 Months to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 27, 2026, 6:21 AM EDT
Completed Phase 2 Interventional Results available

Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab

NCT04306965
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Apremilast
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 27, 2026, 6:21 AM EDT
Completed Phase 2 Interventional

Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis

NCT03394677
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
RVT-501 0.5% ointment, Vehicle ointment
Drug
Lead sponsor
Dermavant Sciences GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Los Angeles, California • Oklahoma City, Oklahoma • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 27, 2026, 6:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Leukotriene Antagonism in Recruitment of CD49d Expressing Neutrophils in Atopic Subjects

NCT03039101
View directory record Official record
Conditions
Nasal Allergy
Interventions
Nasal lavage, Nasal allergen challenge, Epicutaneous skin testing, Peripheral blood, Montelukast 10Mg Tablet, Placebo Oral Tablet
Procedure · Drug
Lead sponsor
Mitchell Grayson
Other
Eligibility
21 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 27, 2026, 6:21 AM EDT
Recruiting No phase listed Observational

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis

NCT06627335
View directory record Official record
Conditions
Pregnancy Related, Atopic Dermatitis
Interventions
Ruxolitinib Cream, TCS
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
14 Years and older · Female only
Enrollment
5,621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 27, 2026, 6:21 AM EDT
Not yet recruiting Phase 4 Interventional

AD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes

NCT07856134
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab-lbkz
Biological
Lead sponsor
Forefront Dermatology S.C
Other
Eligibility
12 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
10
States / cities
Mobile, Alabama • Crest Hill, Illinois • Libertyville, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 27, 2026, 6:21 AM EDT
Active, not recruiting Phase 2 Interventional

Seal, Stopping Eczema and Allergy Study

NCT03742414
View directory record Official record
Conditions
Eczema, Infantile, Eczema, Atopic Dermatitis Eczema, Atopic Dermatitis
Interventions
Tri-lipid skin barrier cream (Epiceram), Fluticasone propionate Cream 0.05%, Standard of Care
Combination Product · Other
Lead sponsor
Kari Nadeau, MD, PhD
Other
Eligibility
1 Week to 12 Weeks
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
4
States / cities
Palo Alto, California • Denver, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 27, 2026, 6:21 AM EDT
Completed Phase 2 Interventional

A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

NCT06436183
View directory record Official record
Conditions
Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
Interventions
Camoteskimab, Placebo
Drug
Lead sponsor
Apollo Therapeutics Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
30
States / cities
Phoenix, Arizona • Encinitas, California • Fountain Valley, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 27, 2026, 6:21 AM EDT
Completed Phase 2 Interventional Results available

Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis

NCT01941537
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ILV-094, Placebo Comparator
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 27, 2026, 6:21 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis

NCT03916081
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Roflumilast Cream 0.05%, Roflumilast Cream 0.15%, Vehicle Cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
17
States / cities
Scottsdale, Arizona • San Diego, California • Hialeah, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 27, 2026, 6:21 AM EDT
Completed Phase 1Phase 2 Interventional

Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis

NCT04927572
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
FMX114, Vehicle
Drug · Other
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Miami, Florida • Miramar, Florida • Sugarloaf, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 27, 2026, 6:21 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT03533751
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Etokimab, Placebo
Biological · Drug
Lead sponsor
AnaptysBio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
37
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Encino, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 27, 2026, 6:21 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis

NCT04921345
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis
Interventions
Nemolizumab
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
2 Years to 12 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
14
States / cities
Fountain Valley, California • San Diego, California • Vista, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 27, 2026, 6:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Registry for the Atopic Dermatitis Research Network

NCT01494142
View directory record Official record
Conditions
Atopic Dermatitis, Eczema Herpeticum
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Months to 80 Years
Enrollment
3,387 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
9
States / cities
Los Angeles, California • Denver, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 27, 2026, 6:21 AM EDT
Completed No phase listed Observational

Clinical and Immunological Evaluation of Children With Allergies

NCT00102570
View directory record Official record
Conditions
Hypersensitivity, Immediate
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 19 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 27, 2026, 6:21 AM EDT